Table 5 Summary table of the various anticancer treatments ranging from the suppression of oncogene expression to therapies to control the tumoral niche and micro-environment. Table revised and improved from [9]

Suppressor or oncogenic proteins target therapies

• TP53 restoring agents Eprenetapopt APR-246

• MDMs inhibitors Idasanutlin, ALRN-6924 and APG-115

• Fusion transcripts targeting

• EVI1 targeting

• NPM1 targeting

• Hedgehog inhibitors Glasdegib and Benzimidazole Mebendazole

Protein kinase inhibitors

• FLT3 I generation inhibitors (midostaurin, sunitinib, lestauritinib, safarenib)

• FLT3 II generation inhibitors (quizartinib, gilteritinib, crenolanib, LY3012218)

• MEK inhibitor Trametinib

• KIT inhibitors

• PI3K/AKT/mTOR inhibitors

• Aurora inhibitors (MLN8054, Alisertib MLN8237, Barasertib AZD1152), CDK4/6 Inhibitors, CHK1, WEE1, and MPS1 inhibitors

• Polo-like kinase (PLKs) inhibitors (Volasertib, Onvasertib NMS-P937)

• SRC and HCK inhibitors

Epigenetic modulators

• New DNA methyltransferase inhibitors SGI-110, DOT1L inhibitors Pinometostat EPZ-5676, SNDX-5613, KO-539

• Menin-MLL1 inhibitor VTP50469

• Histone Deacetylase inhibitors

• IDH1 and IDH2 inhibitors AG-221 and AG-120

• BET-bromodomain inhibitors

Chemotherapeutic agents

• CPX-351

• Vosaroxin

• Nucleoside analogs

Mitochondrial inhibitors

• Bcl-2, Bcl-xL, and Mcl-1 inhibitors (Venetoclax)

• Caseinolytic protease inhibitors

Antibodies and immunotherapies

• Monoclonal antibodies against CD33, CD44,

• CD47, CD123, CLEC12A

• Immunoconjugates (e.g., GO, SGN33A)

• BiTEs and DARTs

• CAR T cells or genetically engineered TCR

• T cells

• Immune checkpoint inhibitors (PD-1/PD-L1,

• CTLA-4)

• Anti-KIR antibody

• Vaccines (e.g. WT1)

AML environment target therapies

• CXCR4 and CXCL12 antagonists

• Antiangiogenic therapies